Information Provided By:
Fly News Breaks for June 22, 2017
MMSI
Jun 22, 2017 | 11:46 EDT
Piper Jaffray analyst Matt O'Brien said he view the announcement that Merit Medical will be allowed by the FDA to expand the indication for its Embosphere Microspheres to include prostatic artery embolization, or PAE, "quite favorably," as he sees Merit to "essentially be the only company" that can market this approach to doctors. O'Brien, who thinks the market for PAE is well north of $1B annually, keeps an Overweight rating on Merit Medical and encourages investors to build positions.
News For MMSI From the Last 2 Days
There are no results for your query MMSI